Genentech obtains FDA priority review status for Obinutuzumab
The FDA has also accepted the company’s biologics license application (BLA) for obinutuzumab with decision expected by the end of 2013. Designed to attack cells with certain markers
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.